Skip to main content

Falling in Love with a Stock

An analyst spends three months building a 50-page investment thesis on a company. The DCF shows 40% upside. The story is compelling: management is executing a turnaround, the market is skeptical, and patient capital will win. The analyst presents the thesis to the investment committee. It's approved. Money is deployed. The stock rises 15%.

Then quarterly results disappoint. Revenue misses consensus by 2%. The analyst immediately rationalizes: "It's a one-quarter miss; the long-term story is intact." Margin compression? "Temporary; pricing power will drive expansion." Management departure? "The CFO was transitional; the CEO is visionary."

Six months later, the stock is down 10%. The analyst has now spent six months on the thesis, so quitting feels like admitting defeat. The sunk cost of time, plus the emotional attachment to the original idea, becomes a prison. Every piece of contrary evidence gets filtered through a conviction that has become unshakeable.

This is falling in love with a stock. It's the most common mistake among good analysts, because it comes from the same psychological trait that makes them good in the first place: the ability to construct a coherent narrative and defend it rigorously.

Quick definition: Falling in love with a stock is the syndrome where an analyst becomes emotionally attached to an investment thesis and begins selectively interpreting evidence to confirm it, while dismissing contradictory signals. It's the manifestation of confirmation bias applied to a specific holding.

Key Takeaways​

  • Confirmation bias is the tendency to seek out and overweight evidence that supports your existing belief while underweighting or dismissing contrary evidence.
  • The more time and intellectual energy you invest in a thesis, the more you'll resist updating it, even when the underlying facts change.
  • Sunk cost fallacy—the belief that time or money already spent should influence future decisions—is especially powerful in valuation work because the "sunk" time is visible (the 50-page model).
  • The first red flag in a deteriorating thesis is rationalization: "This [miss / event / personnel change] doesn't matter because [reason]."
  • The discipline of mandatory thesis updates—regular, written re-examinations of core assumptions—is one of the few effective defenses against falling in love.

Why Analysts Fall in Love, and Why It's Hard to Resist​

The human brain is a hypothesis-generating machine. It finds patterns, constructs narratives, and then works to defend those narratives. This is adaptive in most contexts: it lets us act with confidence despite incomplete information.

But in valuation analysis, this same trait becomes pathological. You build a thesis (a 50-page DCF, a detailed competitive analysis, a narrative about turnaround catalysts). Your brain has now invested significant cognitive energy in that thesis. The longer you've worked on it, the more you've explained it to others, the more you've learned about the company in support of it—the harder it is to abandon.

Add to this the sunk cost fallacy: you've already spent 100 hours on the thesis. Walking away feels like wasting those 100 hours. Staying the course at least preserves the possibility that you were right all along.

And then comes the investment decision: you've talked the investment committee into allocating capital. Now the reputation cost of being wrong is material. The emotional stakes are higher.

Falling in love is the natural human response to these pressures. The mistake is thinking you're immune to it.

The Mermaid: The Confirmation Bias Cycle in Valuation​

Common Falling-in-Love Mistakes​

1. The Rationalization Cascade​

An analyst builds a thesis: "Company X is a turnaround play with durable competitive advantage and misunderstood margins." Fair value is $120, current price $100. Investment made.

Quarter one: revenue misses. Explanation: "Tough comps; the underlying business is strong." Model unchanged.

Quarter two: margin compression. Explanation: "One-time inflation in freight; normalized margins return in Q4." Terminal margin assumption unchanged.

Quarter three: customer churn, magnitude worse than expected. Explanation: "Customers are consolidating; we'll capture more from fewer, bigger customers." Long-term growth assumption unchanged.

By quarter four, the stock is down 20% and the analyst has rationalized away three material deteriorations. Each time, the core thesis—and the analyst's conviction—remained intact. The model now has 15 footnoted assumptions explaining why current results don't reflect underlying reality.

This is falling in love in real time. The stock isn't the problem; the thesis is. But the thesis is too psychologically embedded to revisit.

2. Sunk Cost Trap: Time and Visibility​

An analyst publishes a 50-page equity research note on Company X, arguing it's a buy. The note gets circulation internally and externally. Colleagues cite it. The analyst has been identified, in their own mind and others', as the expert on this name.

Now new information emerges that contradicts the thesis. Updating the recommendation requires admitting the original analysis was wrong—not just slightly off, but in a material way. The sunk cost (visibility, reputation) of the original call makes that update psychologically expensive.

Instead, the analyst finds a reason to maintain the buy rating: "The market has already repriced; our long-term thesis remains intact." This preserves the original recommendation while allowing the analyst to feel ahead of the crowd.

3. The Echo Chamber Effect in Model Building​

Once you've built a 50-page model with a $120 fair value, every conversation with management, every peer conversation, every industry conference is filtered through the lens of that model. You ask leading questions: "When do you expect turnaround benefits?" Instead of neutral ones: "What are the key risks to your business model?"

You go to the industry conference looking for validation of your thesis, and you find it—because confirmation bias is a powerful filter. Speakers who validate your thesis, you remember. Speakers who contradict it, you dismiss as not understanding the company's unique situation.

The model, which should be a tool for testing the thesis, becomes a vehicle for reinforcing it.

4. Overweighting Management Confidence​

An analyst has a long conversation with the CEO, who exudes confidence: "We're investing to capture market share; profitability will follow in 18 months. We've done this before." The analyst leaves the meeting convinced and updates the model to reflect the CEO's confidence.

But the analyst has fallen for the CEO's narrative, which is the CEO's job to sell. An objective analyst would ask: "How many times has the CEO executed this exact playbook? When?" And then benchmark against history.

Instead, the analyst treats the meeting as validation: the CEO is credible; therefore the thesis is correct. This is confusing charisma with evidence.

5. The Asymmetric Confidence in Base Case Assumptions​

A valuation model typically has a "base case" (most likely) and bull/bear scenarios. An analyst in love with the thesis will assign 60–70% probability to the base case, which is the thesis—and only 15–20% each to bear and bull cases.

An objective analyst would ask: given the uncertainty in a 10-year forecast, is a base case really that much more likely than bull or bear? Probably not. A more honest distribution might be 35% base, 30% bull, 35% bear.

But assigning higher probability to the base case protects the original thesis. If the model says the stock is worth $120 in the base case and $85 in the bear case, and the bear case is "only" 20% likely, the analyst can argue the risk/reward is attractive: "Even if the bear case hits, we're only down 15% from here."

That math is comforting. It's also wrong if the bear case is actually more likely than 20%.

6. Ignoring Catalyst Timing and Shifting Goalposts​

An original thesis might have a catalyst: "Management will announce a strategic review by Q2 2024, which will reset investor sentiment." The analyst markets this catalyst. Investors buy. Q2 2024 arrives, and there's no announcement.

Instead of reconsidering the thesis, the analyst shifts the goalpost: "The strategic review will likely happen in Q3." When Q3 comes and goes without an announcement, the goalpost shifts again: "Q4 or early 2025."

By the time the analyst gives up on the catalyst, the stock is down 30% and two years have passed. The thesis was right in direction (improvement is coming) but wrong in timing (when). That's still a failed thesis, but the analyst has reframed it as "right story, wrong timing," which sounds less like a mistake.

Real-World Examples​

Tesla Bull Case in Recession (2022–2023)

Many Tesla bulls built theses in 2021–2022 around autonomous driving, energy storage, and a path to $300+ billion in revenue. In 2023, when demand cratered and the company cut prices aggressively, the narrative adapted: "This is the classic growth phase; Tesla sacrifices profit for volume. Margins will return." The base case margins remained stable in models even as realized margins compressed.

The thesis was adapted, not abandoned. Tesla might still be a great long-term company, but the 2023 thesis wasn't the same as the 2021 thesis—yet it was defended with the same conviction. The analyst who stuck with a "hold" in 2022 when sentiment turned was objectively more accurate than the one who said "buy more on weakness," even if Tesla ultimately works out.

Theranos and the Visionary Founder Halo (2010–2018)

Theranos raised billions at a $9 billion valuation in 2015 based on an unproven technology and a charismatic founder. Investors fell in love with the founder's vision and the narrative of disrupting blood testing.

When evidence emerged that the technology didn't work (red flags from employees, regulators, partners), investors rationalized it: "Theranos is in the trough of disillusionment; all transformative companies face skepticism." The founder's confidence became evidence of correctness. A healthy skepticism would have asked: "If the technology works, why haven't we seen verified, independent test results?"

Instead, investors conflated the founder's charisma with evidence of capability.

GE's Acquisition Binge (2002–2008)

Analysts built bullish theses on GE under CEO Jeff Immelt based on a vision of "diversified industrials with financial services." The narrative was compelling: GE Capital would stabilize earnings through cycles; industrial operations would grow. Analysts modeled this vision into 7–8% long-term growth forecasts.

Then the financial crisis hit, and GE's leverage nearly broke the company. The thesis had assumed a stable credit environment and had rationalized away GE Capital's risks as "diversifying." When the crisis came, the model broke, but the thesis had been so embedded that many analysts kept the "buy" rating even as the stock cratered 60%.

Zoom's Pandemic Boost Extrapolation (2020–2021)

Zoom's stock soared during the COVID-19 pandemic as remote work exploded. Analysts built models assuming Zoom would remain in the $300–400 range, capturing a permanent shift to hybrid work. Some modeled 30%+ growth indefinitely.

By 2022, as companies returned to offices and saturation set in, growth slowed to single digits. Analysts who'd fallen in love with the "permanent remote work" thesis had to scramble. Those who'd modeled growth as temporary and cyclical were closer to reality.

Common Mistakes Section​

Mistake 1: Not Writing Down the Original Thesis and Its Key Assumptions​

If you don't document what would prove your thesis wrong, you'll rationalize any contrary evidence. Write it down: "If revenue growth falls below 5% for two consecutive quarters, the thesis is broken." Then follow it.

Mistake 2: Assigning Too-High Probability to Base Case​

Distributing 70% to base case, 15% each to bull and bear, is overconfident. For a 10-year forecast, 33–40% each to three scenarios is more honest. If base case is more likely, that might be evidence you haven't stress-tested enough.

Mistake 3: Trusting Management Narrative Over Exhibited Results​

Management says "We have pricing power and will expand margins." But results show margin compression. The analyst updates management's narrative into the model instead of updating the narrative based on results.

Mistake 4: Moving Catalyst Dates Without Reassessing the Thesis​

A catalyst (strategic review, turnaround benefits, new product launch) is delayed twice. Instead of reconsidering whether the catalyst will ever happen, the analyst delays the date again. After three delays, the thesis should be questioned, not just re-timed.

Mistake 5: Only Seeking Confirming Information at Conferences or Calls​

Before an earnings call or management meeting, decide what information would support or contradict the thesis. Then listen neutrally. Don't go looking for validation; go looking for evidence.

Mistake 6: Increasing Position Size After Losses Due to Thesis Conviction​

"I was right about the thesis; I'm just early" is the dangerous mantra. Averaging down on conviction without reassessing whether the thesis is still sound is how positions become career-threatening losses.

FAQ​

Q: How do I know if I'm falling in love with a stock vs justifiably holding conviction?

A: Ask yourself: Would I make this recommendation to someone else if I had no track record on it? If your recommendation is influenced by how long you've been bullish or by how many people you've convinced, you're in love. If you'd make the same recommendation to a stranger as to your investment committee, you're thinking clearly.

Q: What's the difference between conviction and stubbornness?

A: Conviction is defended with evidence and updated as evidence changes. Stubbornness is defended with narrative and rationalization. If new data arrives and you update your base case, you have conviction. If new data arrives and you explain why it doesn't matter, you're being stubborn.

Q: Should I sell the stock if I think I'm falling in love with it?

A: Not necessarily. First, do a thesis rewrite: pretend you're starting fresh with the current facts. What fair value do you arrive at? What probability distribution over outcomes? If it's substantially different from your original thesis, exit or significantly reduce. If it's similar, maybe you were right and you're not falling in love. But if you find yourself hedging, rationalizing, or adjusting probabilities upward, that's a signal to reassess.

Q: How do I avoid falling in love while still building conviction?

A: Maintain a "thesis kill list"—specific facts that, if true, would falsify the thesis. "Revenue growth falls below 3% for two quarters" or "Operating margin compresses below 15% on a run-rate basis." If any of those conditions hit, you exit or materially revise. This sounds obvious but is psychologically hard to execute.

Q: What should I do when I realize I've fallen in love with a stock?

A: Do a clean reassessment. Imagine you're pitching the stock fresh to your committee, using only current facts (ignore sunk time). If you wouldn't pitch it at the current price with current facts, exit. If you would, congrats—you've separated conviction from attachment.

Q: Is there a way to use confirmation bias as a tool instead of being trapped by it?

A: Yes: use it to stress-test. Once you have a thesis, ask someone else to "shoot holes" in it. Then, with their critique in mind, play devil's advocate. Actively seek the strongest argument against your thesis and sit with it for 24 hours. If you can refute it cleanly, your thesis is stronger. If you can't, your thesis is weaker than you think.

  • Confirmation Bias — The broader psychological tendency to seek out and overweight evidence supporting existing beliefs while dismissing contradictory evidence. Falling in love is confirmation bias applied to a specific investment.
  • Sunk Cost Fallacy — The belief that money or time already spent on something should influence future decisions. Logically, it shouldn't; only forward-looking facts matter. Psychologically, it's irresistible.
  • Narrative Fallacy — The human tendency to construct coherent stories even when the data doesn't support them. An analyst in love with a stock constructs narratives (rationalizations) that explain away contrary evidence.
  • Post-Decision Dissonance — After making a public recommendation or investment, you experience psychological pressure to defend it, making you more resistant to disconfirming evidence.
  • Pre-Mortem Analysis — A technique where you imagine the thesis has failed catastrophically and then work backward to ask what went wrong. This forces consideration of risks and failure modes you might otherwise rationalize away.

Summary​

Falling in love with a stock is the occupational hazard of good analysis. Good analysts can construct coherent narratives and defend them rigorously. That same skill, when married to sunk time costs and ego investment, becomes a trap.

The defense is discipline: write down the thesis, specify what would falsify it, stress-test assumptions, and maintain a neutral posture toward new information. Before an earnings call or update, list the facts that would support and contradict the thesis. Then listen without filtering.

When you catch yourself rationalizing a miss ("It's temporary," "The CEO said this was planned," "Long-term thesis is intact"), that's a warning sign. It's not proof that you're wrong, but it's a signal to pause and reassess. Do a clean rewrite of the thesis. Would you make this call today using only current facts? If not, exit. If yes, good—you've separated conviction from attachment.

The hardest part isn't the analysis; it's the psychology. Good analysts are confident, thoughtful, and detail-oriented—the exact traits that make them susceptible to falling in love. Recognizing that vulnerability is the first step to managing it.

Next​

Read An analyst mistakes checklist to review the most common errors and systematic practices to catch them before they become material errors.

Statistic: A 2018 study of sell-side analyst recommendation changes found that analysts take an average of 6–9 months longer to downgrade a stock they've previously recommended as a buy compared to initiating coverage at the same level of deterioration.